AXSM

Biotech Sector Performance: The biotech sector is experiencing significant stock surges and advancements in trials and regulatory filings, highlighting the importance of distinguishing between short-term price fluctuations and long-term value for investors.

Notable Stock Highlights: Several biotech companies, including Olema Pharmaceuticals, Owlet Inc., and Rigel Pharmaceuticals, have reached new 52-week highs, driven by positive trial results and strategic offerings.

Upcoming Developments: Companies like Jazz Pharmaceuticals and Tarsus Pharmaceuticals are preparing for important regulatory submissions and clinical trials, indicating ongoing innovation and potential market impact.

Financial Outlooks: Firms such as Natera and Kiniksa Pharmaceuticals have provided updated revenue guidance for 2025, reflecting growth expectations and strategic advancements in their respective fields.

Proposed Class Action Settlement: A proposed class action settlement of $7,750,000 has been approved by the U.S. District Court for the Southern District of New York for purchasers of Axsome Therapeutics, Inc. common stock during the period from May 10, 2021, to April 22, 2022.

Settlement Hearing Details: A hearing to determine the fairness and adequacy of the proposed settlement will take place on February 10, 2026, at the U.S. District Court, where the court will also consider the distribution plan for the settlement proceeds.

Claim Submission Requirements: Settlement Class Members must submit a Claim Form by February 3, 2026, to be eligible for a share of the settlement fund; failure to do so will result in being bound by the court's judgment.

Exclusion and Objection Process: Members wishing to exclude themselves from the settlement must submit a written request by January 13, 2026, and any objections to the settlement must also be submitted by the same date.